Human gastrin- releasing peptide receptor expression in women with uterine cervix cancer.
Frontiers in oncology(2023)
Abstract
The frequency of overexpression in this study suggests that Pb-DOTAM-GRPR1 radiopharmaceutical treatment may be useful in the management of persistent, recurrent, or metastatic uterine cervix cancer patients. A phase I clinical trial involving patients with metastatic uterine cervix cancer is currently underway (NCT05283330).
MoreTranslated text
Key words
cervical cancer,gastrin-releasing peptide (GRP) receptor,radiopharmaceutical,uterine cervix adenocarcinoma,uterine cervix cancer
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined